HC Wainwright Predicts RenovoRx’s Q3 Earnings (NASDAQ:RNXT)

RenovoRx, Inc. (NASDAQ:RNXT) – Equities researchers at HC Wainwright upped their Q3 2026 earnings estimates for RenovoRx in a report issued on Friday, August 14th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.03) for the quarter, up from their prior forecast of ($0.08). The consensus estimate for RenovoRx’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for RenovoRx’s Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.04) EPS, FY2028 earnings at $0.08 EPS, FY2029 earnings at $0.18 EPS and FY2030 earnings at $0.26 EPS.

Several other equities research analysts have also issued reports on the company. Weiss Ratings upgraded RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 17th. Wall Street Zen upgraded shares of RenovoRx from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Ascendiant Capital Markets boosted their target price on shares of RenovoRx from $13.50 to $14.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, RenovoRx presently has an average rating of “Moderate Buy” and an average target price of $8.50.

RenovoRx Trading Down 14.3%

RNXT opened at $1.20 on Tuesday. The stock has a fifty day moving average price of $0.96 and a 200 day moving average price of $0.94. RenovoRx has a 1 year low of $0.70 and a 1 year high of $1.50. The stock has a market cap of $54.06 million, a price-to-earnings ratio of -3.87 and a beta of 0.99.

RenovoRx (NASDAQ:RNXT) last released its earnings results on Wednesday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. The company had revenue of $0.91 million during the quarter, compared to analyst estimates of $0.70 million. RenovoRx had a negative return on equity of 138.07% and a negative net margin of 621.71%.

Hedge Funds Weigh In On RenovoRx

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. AIGH Capital Management LLC raised its stake in RenovoRx by 30.8% during the 1st quarter. AIGH Capital Management LLC now owns 3,706,197 shares of the company’s stock valued at $3,682,000 after purchasing an additional 872,303 shares during the last quarter. Wealthspire Advisors LLC acquired a new stake in RenovoRx in the 4th quarter worth $212,000. Citadel Advisors LLC bought a new position in shares of RenovoRx during the 3rd quarter worth about $154,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of RenovoRx during the second quarter valued at about $98,000. Finally, Bleichroeder LP lifted its stake in shares of RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after buying an additional 61,379 shares during the period. Institutional investors own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.